I agree that "... the right kind of clinical guidance will matter more than it does today" and, like the meds, this doesn't have to be one-size fits all for an individual or across all stages. Getting a full picture of a person's situation is key at the outset, but as they succeed/progress their needs & outlook will change.
Two things missing ... meaningful financial incentives for individuals who maintain weight loss/better metabolic health. There are mini-incentives (points exchangeable for discounts on goods/services) but I think there's a place to pay people larger bounties based on duration of success (allowing for some variation around a baseline reset). Right now, no tangible value is flowing to the people who matter most to realizing long-term value.
Second possibility ... as prices come down and cluster around price points, it becomes possible to market levels of service with drugs included in the price (injectables or orals, on-boarding with one and switching to the other, depending on success in either phase). The outset may be have a step-up in non-clinical services once a person starts responding to a drug/form and then a step-down once they attain, with bounties as they maintain them over time.
Great interview!
I agree that "... the right kind of clinical guidance will matter more than it does today" and, like the meds, this doesn't have to be one-size fits all for an individual or across all stages. Getting a full picture of a person's situation is key at the outset, but as they succeed/progress their needs & outlook will change.
Two things missing ... meaningful financial incentives for individuals who maintain weight loss/better metabolic health. There are mini-incentives (points exchangeable for discounts on goods/services) but I think there's a place to pay people larger bounties based on duration of success (allowing for some variation around a baseline reset). Right now, no tangible value is flowing to the people who matter most to realizing long-term value.
Second possibility ... as prices come down and cluster around price points, it becomes possible to market levels of service with drugs included in the price (injectables or orals, on-boarding with one and switching to the other, depending on success in either phase). The outset may be have a step-up in non-clinical services once a person starts responding to a drug/form and then a step-down once they attain, with bounties as they maintain them over time.